Processes in atherogenesis: complement activation.

The complement system consists of a complex group of plasma proteins, which, on activation, lead to a cascade of interactions culminating in the production of a variety of pro-inflammatory molecules. The system also contains cellular receptors for complement fragments produced during activation and regulatory molecules. It is part of the innate immune system representing humoral defence, but in certain circumstances may itself contribute to disease. In the formation of atherosclerotic lesions, there are two outstanding cellular phenomena, monocyte recruitment, with subsequent development of lipid-filled foam cells and smooth muscle cell activation. Subendothelial deposition of low density lipoprotein appears to be an important stimulus in these events and substantial evidence suggests that complement activation may be a link between lipoprotein deposition and subsequent lesion development.

[1]  G. Dahlén,et al.  Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. , 1995, Atherosclerosis.

[2]  C. Carter,et al.  Meeting summary , 1984 .

[3]  G. Gresham,et al.  Atherosclerosis induced in hypercholesterolaemic baboons by immunological injury; and the effects of intravenous polyunsaturated phosphatidyl choline. , 1971, Atherosclerosis.

[4]  K. Resch,et al.  Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. , 1987, Journal of immunology.

[5]  P. Lachmann,et al.  Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Devine,et al.  Characterization of kinetics and target proteins for binding of human complement component C3 to the surface-exposed outer membrane of Chlamydia trachomatis serovar L2 , 1993, Infection and immunity.

[7]  H. Müller-Eberhard,et al.  Anaphylatoxins: C3a and C5a. , 1978, Advances in immunology.

[8]  J. Smiley,et al.  Immune-complex vasculitis: role of complement and IgG-Fc receptor functions. , 1989, The American journal of the medical sciences.

[9]  G. Weissmann,et al.  Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. , 1974, Journal of immunology.

[10]  W. Hollander,et al.  Soluble proteins in the human atheroschlerotic plaque , 1979 .

[11]  K. Miyazono,et al.  Induction of transforming growth factor-beta during cardiac allograft rejection. , 1993, Journal of immunology.

[12]  M. Reidy,et al.  Role of basic fibroblast growth factor in vascular lesion formation. , 1991, Circulation research.

[13]  C. Esmon,et al.  Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. , 1990, The Journal of biological chemistry.

[14]  H. Rus,et al.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. , 1985, Atherosclerosis.

[15]  M. Debakey,et al.  Cytomegalovirus and atherosclerosis. , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[16]  C. Rackley,et al.  Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. , 1996, American heart journal.

[17]  U. Faire,et al.  Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease , 1995, Journal of internal medicine.

[18]  H. Rus,et al.  Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. , 1986, Atherosclerosis.

[19]  I. Roth,et al.  CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. , 1992, Atherosclerosis.

[20]  M. Kazatchkine,et al.  The complement system in atherosclerosis. , 1988, Atherosclerosis.

[21]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[22]  B. Morgan,et al.  Complement: Clinical Aspects and Relevance to Disease , 1991 .

[23]  G. Hansson,et al.  Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[24]  P. Ward,et al.  Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. , 1995, Journal of immunology.

[25]  A. Bengtsson,et al.  IgG binding to cytoskeletal intermediate filaments activates the complement cascade. , 1987, Experimental cell research.

[26]  M. Schönermark,et al.  C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. , 1990, Kidney international.

[27]  D. Davies.  Hypothesis. An immunological view of atherogenesis. , 1969, Journal of atherosclerosis research.

[28]  C. Minick,et al.  EXPERIMENTAL INDUCTION OF ATHERO-ARTERIOSCLEROSIS BY THE SYNERGY OF ALLERGIC INJURY TO ARTERIES AND LIPID-RICH DIET , 1966, The Journal of experimental medicine.

[29]  H. Jacob,et al.  Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. , 1981, The Journal of laboratory and clinical medicine.

[30]  S. Bhakdi,et al.  Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions , 1990, The Journal of experimental medicine.

[31]  C. Gerard,et al.  C5A anaphylatoxin and its seven transmembrane-segment receptor. , 1994, Annual review of immunology.

[32]  N. Simionescu,et al.  Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. , 1986, The American journal of pathology.

[33]  V. Tertov,et al.  Autoantibodies against low-density lipoprotein and atherogenic potential of blood. , 1993, Annals of medicine.

[34]  G. Hansson,et al.  Complement receptors and regulatory proteins in human atherosclerotic lesions. , 1989, Arteriosclerosis.

[35]  S. Bhakdi,et al.  [Functions and relevance of the terminal complement sequence]. , 1990, Immunitat und Infektion.

[36]  E. Leonard,et al.  Human monocyte chemoattractant protein-1 (MCP-1). , 1990, Immunology today.

[37]  S. Bhakdi,et al.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.

[38]  H. Rus,et al.  Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. , 1989, Atherosclerosis.

[39]  A. J. Day,et al.  Changes in aortic cholesterol-esterifying activity in rabbits fed cholesterol for three days. , 1974, Atherosclerosis.

[40]  J. Halperin,et al.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.

[41]  A. Agostoni,et al.  Complement system in coronary heart disease: a review. , 1995, Immunopharmacology.

[42]  G. Hansson,et al.  Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[43]  T. Hugli,et al.  Biologic activity of synthetic analogues of C5a anaphylatoxin. , 1992, Journal of immunology.

[44]  B. Morgan.  Effects of the membrane attack complex of complement on nucleated cells. , 1992, Current topics in microbiology and immunology.

[45]  P. Lachmann,et al.  The control of homologous lysis. , 1991, Immunology today.

[46]  M. Leinonen,et al.  Chronic Chlamydia pneumoniae Infection as a Risk Factor for Coronary Heart Disease in the Helsinki Heart Study , 1992, Annals of Internal Medicine.

[47]  S. Schwartz,et al.  Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.

[48]  J. Resau,et al.  Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. , 1988, The American journal of pathology.

[49]  H. Rus,et al.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. , 1987, Clinical and experimental immunology.

[50]  H. Müller-Eberhard,et al.  Release of histamine from rat mast cells by the complement peptides C3a and C5a. , 1975, Immunology.

[51]  H. Sørensen,et al.  Complement and arteriosclerosis. , 1973, Atherosclerosis.

[52]  M. Hsieh,et al.  Acute endothelial reperfusion injury after coronary artery bypass grafting. , 1994, The Annals of thoracic surgery.

[53]  R. Poston,et al.  Immunity and inflammation in the pathogenesis of atherosclerosis. A review. , 1974, Atherosclerosis.

[54]  C. M. Blow,et al.  Nicotine and cigarette smoking: effects on the ultrastructure of aortic endothelium. , 1990, International journal of experimental pathology.

[55]  R. Snyderman,et al.  Chemotactic and Anaphylatoxic Fragment Cleaved from the Fifth Component of Guinea Pig Complement , 1968, Science.

[56]  P. Sims,et al.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. , 1989, The Journal of biological chemistry.

[57]  H. Kruth,et al.  Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. , 1984, The American journal of pathology.

[58]  C. Mackay,et al.  Expression of monocyte chemoattractant protein‐1 and interleukin‐8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential , 1996, European journal of immunology.

[59]  H. Rus,et al.  Immunoglobulins and complement components in human aortic atherosclerotic intima. , 1985, Atherosclerosis.

[60]  G. Hansson,et al.  Immune mechanisms in atherogenesis. , 1994, Annals of medicine.

[61]  R. Thompson,et al.  REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS , 1970, The Journal of experimental medicine.

[62]  D. Siscovick,et al.  Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. , 1992, JAMA.

[63]  W. Parks,et al.  Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. , 1995, Journal of immunology.

[64]  A. Fogelman,et al.  Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. , 1989, Journal of lipid research.

[65]  J. Warren,et al.  The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. , 1996, The American journal of pathology.

[66]  G. Hansson,et al.  Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. , 1989, The Journal of clinical investigation.

[67]  P. Ward,et al.  C5a-induced expression of P-selectin in endothelial cells. , 1994, The Journal of clinical investigation.